Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

Legendary <keyword id="19918921" type="General" weightage="20" keywordseo="Hollywood-actor" source="keywords">Hollywood actor</keyword> <keyword id="20740436" type="General" weightage="100" keywordseo="Al-Pacino" source="keywords">Al Pacino</keyword>, known for his iconic roles in The Godfather trilogy and Scarface, recently opened up about a terrifying moment during the <keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">COVID-19</keyword> pandemic when he thought he had "experienced death." The 84-year-old actor, in an interview with <keyword id="20038431" type="General" weightage="20" keywordseo="People-magazine" source="keywords" meta.keywordsubtype="org" meta.entityname="People magazine" meta.hostid="261" meta.entityid="People magazine">People magazine</keyword>, recounted how he fainted while battling the virus in 2020 and was left questioning his very existence when a nurse attending to him couldn’t detect a pulse. Pacino revealed that it was his "great assistant" Michael Quinn who quickly acted, summoning paramedics to his <keyword id="19914983" type="General" weightage="20" keywordseo="Los-Angeles" source="keywords">Los Angeles</keyword> home. "He got the people coming, because the nurse that was taking care of me said, 'I don't feel a pulse on this guy,'" Pacino recalled, describing the scene as something straight out of a movie. For a brief moment, the actor believed he had passed away. "I thought I experienced death," Pacino said, "because how did all those people gather together? There was an ambulance in front of my house, six paramedics in my living room, and two of my doctors in space suits. I opened my eyes and thought, 'What happened to me?'" But despite the dramatic circumstances, Pacino doesn’t seem too shaken by the ordeal. "Everybody thought I was dead. I didn't," he said. "If I was dead, I fainted. And when I came to, it was all gone." Quoting Shakespeare's famous line from Hamlet—“To be, or not to be”—Pacino mused on the fragility of life but admitted the experience didn’t leave any lasting change on how he lives. When asked whether the health scare had any effect on his outlook, Pacino simply responded, "Not at all." Pacino, who has lived a life filled with memorable roles, fame, and critical acclaim, seems to be taking this near-brush with death in stride. In fact, he’s keeping busy, with his upcoming memoir *Sonny Boy* on the horizon and a role in <keyword id="19920478" type="General" weightage="20" keywordseo="Johnny-Depp" source="keywords">Johnny Depp</keyword>'s directorial project *Modi - Three Days on the Wing of Madness*, which is set for a December 5 release. While many may see such a health scare as a turning point, Pacino remains remarkably unchanged by it. His outlook on life and death, much like his characters on screen, is marked by a sense of calm amidst the chaos. Whether fainting during a pandemic or standing before the camera, Pacino's resilient spirit continues to define him as one of Hollywood's most enduring stars.

'I thought I experienced death': Al Pacino talks about battling Covid-19

A week or two of cold and cough can make you conjure up some pretty odd conspiracy theories. The freshest one that I cooked up this week is that 'Big Tissue' wishes to keep everyone sick, and therefore they collaborate with 'The Scientists' to keep them from making a cure. After all, the world witnessed researchers demonstrate incredible and hasty success in combating <keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">COVID-19</keyword>, and yet, the <keyword id="20237676" type="General" weightage="100" keywordseo="common-cold" source="keywords">common cold</keyword> remains an seemingly elusive target. But far from being an actual conspiracy, there are several real reasons why we haven’t yet cracked the code to curing the cold, despite decades of research. So grab your tissues, folks, and let's get into them. <h2><keyword id="23387393" type="General" weightage="20" keywordseo="viral-diversity" source="keywords">Viral diversity</keyword></h2>One major hurdle in curing the common cold is the sheer diversity of viruses involved. Over 200 viruses can cause cold symptoms, with <keyword id="23387392" type="General" weightage="20" keywordseo="rhinoviruses" source="keywords">rhinoviruses</keyword> responsible for up to 75% of cases. Rhinoviruses alone consist of more than 160 known strains. This viral diversity makes it extremely difficult to develop a universal vaccine or treatment. Unlike SARS-CoV-2, which has one main spike protein target, cold viruses come in a dizzying array of structures and behaviours, requiring a vast array of medical solutions. In contrast, when COVID-19 emerged, researchers focused primarily on one virus and one major target — its spike protein. That focus allowed for the rapid development of <keyword id="19953288" type="General" weightage="20" keywordseo="vaccines" source="keywords">vaccines</keyword> using mRNA technology, like those from Pfizer and Moderna. For the common cold, a similar solution isn’t feasible due to the multiple viral families involved. <h2><keyword id="20862236" type="General" weightage="20" keywordseo="mutations" source="keywords">Mutations</keyword> and adaptations</h2>Another issue is how quickly cold viruses mutate. Rhinoviruses, for example, are known for their high mutation rates. This rapid evolution allows them to evade the immune system, which is why even if you’ve had a cold before, you're not immune to future infections from different strains. <div type="Article" hostid="261" msid="113757960" title="Healthcare in India faces massive strain as costs rise by 14% annually; most expenses paid out-of-pocket" mstype="2" mssubtype="0"></div>This rapid mutation is akin to how COVID-19 has evolved into variants, but with cold viruses, it happens on an even greater scale. Scientists fear that if they developed a vaccine, new strains would quickly render it ineffective, much like how seasonal flu vaccines must be reformulated annually. <h2>Mildness of the illness</h2>Ironically, one reason the common cold hasn’t been cured is because it’s too mild to warrant massive investment. Most people recover from a cold without medical intervention. While cold symptoms are annoying — runny nose, sore throat, cough — they rarely escalate into serious illness. As a result, pharmaceutical companies and governments have little financial incentive to pour billions into research for a disease that poses no significant threat to public health. COVID-19, on the other hand, caused severe illness and death on a global scale, spurring massive investment from both the public and private sectors. Governments and companies alike invested heavily in research and fast-tracked vaccines, which led to solutions much quicker than we’ve seen for colds. <h2>Complex, complex immune system</h2>The immune system’s response to cold viruses is also a significant factor. Studies have shown that repeated exposure to cold viruses over a lifetime results in limited immunity. For instance, research from Harvard points out that even though the body produces antibodies after a cold, the <keyword id="20082133" type="General" weightage="20" keywordseo="immune-response" source="keywords">immune response</keyword> isn't strong enough to prevent future infections from slightly different strains. This is in stark contrast to diseases like measles, where one infection can result in lifelong immunity. COVID-19 benefitted from its novelty. The immune system had never encountered SARS-CoV-2 before, making it easier to target with vaccines that produce a strong and specific immune response. Here’s an additional fun fact: because there are SO many different strains of common cold-causing viruses, research says that it is unlikely that you will be infected with the same strain of common cold twice throughout your life! <h2>Attempts to develop treatments</h2>There have been attempts to develop treatments for the common cold. Some researchers have targeted the way viruses enter and replicate in human cells. For example, a 2018 study explored inhibiting the protein that cold viruses use to replicate, showing some promise in early trials. However, most of these treatments are in the experimental phase, and none have been widely successful yet. <div type="Article" hostid="261" msid="113284254" title="Gastro problems could heighten Parkinson&amp;#39;s disease risk by 76%, study finds" mstype="2" mssubtype="0"></div>In recent years, attention has shifted towards using broad-spectrum antiviral drugs that can target multiple viruses at once, similar to how some antibiotics work against a range of bacteria. However, this approach has yet to yield a major breakthrough. The idea of a universal cure for the common cold remains distant, but advances in genetic research and vaccine technology offer some hope. For example, CRISPR technology may allow scientists to edit out the genetic components that cold viruses rely on to replicate. Additionally, the mRNA technology used for COVID-19 vaccines has opened new possibilities for antiviral treatments, although these applications are still in early stages. Research continues, but for now, humanity may have to continue battling sniffles and coughs the old-fashioned way: with rest, fluids, and time.

How did we manage to deal with COVID-19 so quickly, but the common cold still remains a persisting problem?

The <keyword id="22407175" type="General" weightage="100" keywordseo="U-WIN" source="keywords">U-WIN</keyword> portal, a replication of the <keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">Covid-19</keyword> vaccine management system Co-WIN, is set for a pan-India launch likely by the end of August, aiming to maintain an electronic registry of routine immunisations, official sources said. Currently, U-WIN is in pilot mode across all states and Union Territories, except for West Bengal, which is yet to start uploading data, the sources told PTI, adding that it is still under consideration in the state. The U-WIN platform captures every <keyword id="19933690" type="General" weightage="20" keywordseo="vaccination" source="keywords">vaccination</keyword> event for pregnant women and children under the Universal Immunization Programme (UIP). Minister of Finance <keyword id="19916618" type="General" weightage="20" keywordseo="nirmala-sitharaman" source="keywords">Nirmala Sitharaman</keyword> had announced in the interim Budget for 2024-2025 that U-WIN, along with intensified efforts under Mission Indradhanush, will be rolled out nationwide for managing <keyword id="21423640" type="General" weightage="20" keywordseo="immunisation" source="keywords">immunisation</keyword>. "The U-WIN will ensure timely administration of vaccine doses by digitally recording every vaccination event under the Universal Immunisation Programme among all pregnant women and children aged 0-5 years," an official told PTI. "The portal will target 2.9 crore pregnant women and 2.6 crore infants (0-1 years) annually by providing 11 vaccines against 12 vaccine preventable diseases -- diphtheria, measles, rubella, and tetanus through more than 1.2 crore vaccination sessions across the country," the official added. The platform generates a uniform QR-based, digitally verifiable e-vaccination certificate, similar to Covid vaccination certificate, which can be accessed anytime by the citizens through a single click. Vaccination records under UIP are being maintained manually as of now. So this will do away with the hassle of keeping a physical record, the officials explained. It will enable the digitisation of session planning, and updating vaccination status on a real-time basis, they added. "Also, there is no mechanism of individual tracking. There is also lack of awareness among beneficiaries about session location and date especially in urban areas and iniquity in immunisation coverage in states and UTs," another official said. "Besides, another major issue is that immunisation at private health facilities is not recorded," the official added. The U-WIN is going to be the single source of information for immunisation services which will record pregnancy details and outcome, newborn registration and immunisation at birth. It will update vaccination status, and delivery outcome, among others, on real time, the official said. As of July 9, 2024, the pilot has registered 5.33 crore beneficiaries on U-WIN. Over 83.55 lakh vaccination sessions have been digitally conducted, and 18.15 crore vaccine doses have been recorded. The platform aims to reduce zero-dose and left-out children through a name-based tracking mechanism and empower citizens with anytime, anywhere access to vaccination services, particularly benefiting migratory populations, the official said. "The U-WIN portal is likely to be launched pan <keyword id="19895063" type="General" weightage="20" keywordseo="India" source="keywords">India</keyword> in August end," the official stated. Citizens can self-register for vaccinations via the U-WIN web portal or its Android mobile application, select preferred vaccination centres, and schedule appointments. Automated SMS alerts inform citizens about registration confirmations, administered doses, and upcoming dose reminders, ensuring timely and age-appropriate vaccinations. It also facilitates the creation of Ayushman Bharat Health Account (ABHA) IDs for comprehensive health record maintenance. The U-WIN also supports the frontline workers to digitally record all vaccination events for children and pregnant women for complete, accurate and easy record maintenance, the official said.

Pan-India rollout of U-WIN to track routine immunisations likely by Aug end

The far-reaching consequences of the <keyword id="19955291" type="General" weightage="20" keywordseo="COVID-19-pandemic" source="keywords">COVID-19 pandemic</keyword> have reshaped humanity’s future in ways we are only beginning to understand. This global health crisis didn’t just disrupt lives—it also shattered nearly a decade of global health progress, a startling new report by the <keyword id="19902256" type="General" weightage="20" keywordseo="World-Health-Organisation" source="keywords" meta.keywordsubtype="org" meta.entityname="World Health Organisation" meta.hostid="261" meta.entityid="World Health Organisation">World Health Organisation</keyword> (<keyword id="19895006" type="General" weightage="20" keywordseo="WHO" source="keywords" meta.keywordsubtype="org" meta.entityname="WHO" meta.hostid="261" meta.entityid="WHO">WHO</keyword>) has revealed. According to the <keyword id="21164185" type="General" weightage="20" keywordseo="World-Health-Statistics" source="keywords">World Health Statistics</keyword> 2024 report, the <keyword id="8763838" type="General" weightage="20" keywordseo="COVID-19" source="Orion">COVID-19</keyword> pandemic reversed over a decade of advancements in <keyword id="21716169" type="General" weightage="20" keywordseo="global-life-expectancy" source="keywords">global life expectancy</keyword> within a mere two years. From 2019 to 2021, <keyword id="14078" type="General" weightage="100" keywordseo="life-expectancy" source="Orion">life expectancy</keyword> worldwide plummeted by 1.8 years, dropping to 71.4 years. Similarly, global <keyword id="21842689" type="General" weightage="20" keywordseo="healthy-life-expectancy" source="keywords">healthy life expectancy</keyword> decreased by 1.5 years, falling to 61.9 years. The last time both these levels were so low was back in 2012! The report also underscores the uneven impact of the pandemic across different regions. The WHO regions of Southeast Asia and the Americas were hit the hardest, experiencing a decline in life expectancy by approximately three years and a drop in healthy life expectancy by 2.5 years between 2019 and 2021. In stark contrast, the Western Pacific Region saw minimal effects during the same period, with losses of less than 0.1 years in life expectancy and 0.2 years in healthy life expectancy. Furthermore, COVID-19 swiftly became a leading cause of death, ranking as the third highest globally in 2020 and the second in 2021, claiming nearly 13 million lives during this period. The latest data indicates that, except in the African and Western Pacific regions, COVID-19 was among the top five causes of death, notably becoming the leading cause of death in the Americas for both years. “There continues to be major progress in global health, with billions of people who are enjoying better health, better access to services, and better protection from health emergencies. But we must remember how fragile progress can be,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “In just two years, the COVID-19 pandemic erased a decade of gains in life expectancy. That's why the new <keyword id="21604359" type="General" weightage="20" keywordseo="pandemic-Agreement" source="keywords">Pandemic Agreement</keyword> is so important: not only to strengthen global health security, but to protect long-term investments in health and promote equity within and between countries.” The new Pandemic Agreement, also known as the ‘Pandemic Accord’ or ‘Pandemic Treaty’, is an international pact currently under negotiation by the 194 member states of the WHO. This accord aims to enhance global readiness and response to pandemics, ensuring the world can effectively prevent, prepare for, and respond to future health crises. The negotiation process is spearheaded by the Intergovernmental Negotiating Body (INB), established by the <keyword id="20294860" type="General" weightage="20" keywordseo="world-health-assembly" source="keywords">World Health Assembly</keyword> in 2021. The INB's goal is to finalise the agreement for adoption at the 2024 World Health Assembly, scheduled from May 27 to June 1 in Geneva, Switzerland. This year's Health Assembly theme, ‘All for Health, Health for All,’ underscores the universal commitment to this crucial initiative.

COVID-19 pandemic caused global life expectancy to fall back to 2012 levels, erasing a decade’s worth of progress: WHO

As many as 290 cases of <keyword id="21545939" type="General" weightage="20" keywordseo="KP-2" source="keywords">KP.2</keyword> and 34 cases of <keyword id="21748081" type="General" weightage="20" keywordseo="KP-1" source="keywords">KP.1</keyword>, both sub-lineages of COVID-19 that are responsible for surge in cases in Singapore, have been found in India, according to official data. However, a source in the Union health ministry told PTI that they are all sub variants of <keyword id="20115417" type="General" weightage="20" keywordseo="JN1" source="keywords">JN1</keyword> and there is no associated increase in hospitalisation and severe cases. "So there is no reason for concern or panic. The mutations will keep happening at a rapid pace and this is the natural behaviour of viruses like SARS-CoV2," the source said. The source further said that the INSACOG surveillance is sensitive and is able to pick up the emergence of any new variant and samples are also picked from hospitals in a structured manner to detect any change in the severity of disease due to virus. Data compiled by the Indian SARS-CoV-2 Genomics Consortium (INSACOG) showed that 34 cases of KP.1 have been found across seven states and UTs with 23 cases registered from West Bengal. The other states are Goa (1), Gujarat (2), Haryana (1), Maharashtra (4) Rajasthan (2) and Uttarakhand (1). As many as 290 cases of KP.2 have been registered with Maharashtra reporting the highest number at 148, according to the data. The other states and Union territories are Delhi (1), Goa (12), Gujarat (23), Haryana (3), Karnataka (4), Madhya Pradesh (1), Odisha (17), Rajasthan (21), Uttar Pradesh (8), Uttarakhand (16) and West Bengal (36). Singapore is seeing a new COVID-19 wave as the authorities recorded more than 25,900 cases from May 5 to 11 with KP.1 and KP.2 accounting for over two-thirds of cases in Singapore. Globally, the predominant COVID-19 variants are still JN.1 and its sub-lineages, including KP.1 and KP.2. KP.1 and KP.2 belong to a group of COVID-19 variants scientists have nicknamed 'FLiRT', after the technical names of their mutations. The strains in FLiRT are all descendants of the JN.1 variant, an offshoot of the Omicron variant. KP.2 was classified by the World Health Organization as a Variant Under Monitoring.

290 cases of COVID-19 variant KP.2, 34 cases of KP.1 detected in India: INSACOG data

The pharmaceutical giant <keyword id="19910149" type="General" weightage="20" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword>'s <keyword id="20040659" type="General" weightage="20" keywordseo="COVID-19-vaccine" source="keywords">COVID-19 vaccine</keyword> is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side effect, according to a report in the British Newspaper 'The Telegraph'. AstraZeneca has announced that the <keyword id="19959412" type="General" weightage="20" keywordseo="vaccine" source="keywords">vaccine</keyword> was being removed from markets for commercial reasons. It further said that the vaccine was no longer being made or supplied, having been superseded by updated vaccines that fight new variants. The application to withdraw the vaccine was made on March 5 and came into effect on May 7. The vaccine can be no longer used in the European Union following the company's decision to withdraw its "marketing authorisation." Similar applications will be submitted in the UK and other nations in the coming months that have given a go-ahead to the vaccine, known as Vaxzevria. In recent months, Vaxzevria has come under scrutiny over a very rare side effect, which causes blood clots and low blood platelet counts. In court documents, AstraZeneca in the High Court in February admitted that the vaccine "can, in very rare cases, cause <keyword id="20218859" type="General" weightage="20" keywordseo="TTS" source="keywords">TTS</keyword>". TTS which stands for <keyword id="21475609" type="General" weightage="20" keywordseo="Thrombosis-with-Thrombocytopenia-Syndrome" source="keywords">Thrombosis with Thrombocytopenia Syndrome</keyword> has been associated with at least 81 deaths in the UK and hundreds of serious injuries. More than 50 alleged victims and grieving relatives have filed a lawsuit against AstraZeneca in a High Court case. AstraZeneca has insisted that the decision to withdraw the vaccine is not related to the case or admission that it can cause TTS and termed the timing a pure coincidence, according to The Telegraph report. "We are incredibly proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally. Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic," The Telegraph quoted AstraZeneca as saying. In a statement, the pharmaceutical giant said, "As multiple, variant Covid-19 vaccines have since been developed, there is a surplus of available updated vaccines", adding that it has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied, The Telegraph reported. It further announced its decision to initiate the withdrawal of the marketing authorisations for Vaxzevria within Europe. The company said, "We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic." Last week, AstraZeneca reiterated its commitment to patient safety while emphasising the vaccine's overall safety profile. An AstraZeneca spokesperson had stated, "Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority, and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines." This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its <keyword id="19896627" type="General" weightage="20" keywordseo="covid" source="keywords">Covid</keyword> vaccine Covishield and Vaxzevria "can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)." Despite these rare occurrences, the pharmaceutical company maintained that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy. Regulatory agencies worldwide continue to assert that the benefits of vaccination outweigh the risks of such extremely rare side effects. SEE ALSO:<a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank"></a> <a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank">Aadhar Housing Finance IPO – Price band to risk factors, all you need to know</a><a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank"></a> <a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank">Top-selling cars in India in April 2024 – Tata Punch continues to dominate</a><a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank">Worldwide tablet shipments grow in Q1 2024 after two years of decline</a>

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

<ul><li>Delhi has reported a surge in <keyword id="20233512" type="General" weightage="20" keywordseo="Dengue-cases" source="keywords">dengue cases</keyword>, with 300 new cases reported in the last seven days.</li><li>This takes the total number of dengue cases reported in Delhi to 1,229 in 2024.</li><li>There has also been a rise in malaria and <keyword id="22649903" type="General" weightage="20" keywordseo="Chikungunya-cases" source="keywords">chikungunya cases</keyword>.</li></ul>Delhi has reported over 300 dengue cases in the past seven days, taking the total number of cases in the national capital so far this year to 1,229 as mosquito-borne diseases seemingly are on a slow but steady rise in the city, according to official data. Cases of malaria are considerably higher so far when compared to last year. Delhi has reported 363 malaria cases till this month while the figure stood at 294 in the corresponding month in 2023. As per a PTI report, the total malaria cases last year were 426. Most malaria cases are reported from the West Delhi zone. As for Chikungunya, 43 cases have been reported so far. This is nearly double than last year when the figure stood at 23. A total of 65 cases of the virus were reported last year. The most number of chikungunya cases have been reported from the South Delhi zone this year. Last week, the city witnessed a spike of nearly 250 cases of dengue in seven days. As per Municipal Corporation of Delhi's (MCD) data from January till September 21, a total of 1,229 dengue cases have been reported in the city with the death of a 54-year old registered in Lok Nayak Hospital, a senior official at the hospital had confirmed. Delhi reported 651 cases of dengue this month. Last month, a total of 256 dengue cases were reported in the city. The number of cases has become three-digit since August, it said. Last year, Delhi reported 3,013 dengue cases till the corresponding month, a manifold increase from 525 in 2022. A total of 9,266 cases were reported in the entire year while 19 dengue deaths were registered in the city last year. In September alone, the figure stood at 2,141 cases in 2023. The most number of cases this year are reported from the Najafgarg zone at 180. In a week, 45 cases have been reported in the area, the highest of all the zones besides the south zone where an equal number of cases were reported this week. The non-MCD areas governed by other agencies like NDMC, Delhi Cantt, and Railways, reported 312 dengue cases to the total tally, as per the data. To enforce mosquito control laws, the MCD has issued over 1.14 lakh legal notices and 39,338 challans to those who allowed mosquito breeding on their properties. Repeat offenders have been fined Rs 24.82 lakh, and police complaints have been filed against 9,241 people who didn't follow the rules, as per the data. The civic body also plans to increase fogging operations at major upcoming public events like Dussehra and Durga Puja and step up inspections and anti-larval measures in areas with high mosquito populations to curb the infectivity of the virus. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/sebi-report-reveals-the-ugly-truth-of-fo-trading-in-india-93-of-retail-traders-incurred-losses/articleshow/113620397.cms">SEBI report reveals the ugly truth of F&amp;O trading in India – 93% of retail traders incurred losses</a> <a href="https://www.businessinsider.in/tech/news/gopro-hero-the-companys-smallest-4k-camera-launched-at-23990/articleshow/113591944.cms">GoPro Hero, the company’s smallest 4K camera launched at ₹23,990</a> <a href="https://www.businessinsider.in/business/telecom/news/jio-and-airtel-lost-subscribers-in-july-after-tariff-hike-bsnl-records-growth/articleshow/113548793.cms">Jio and Airtel lost subscribers in July after tariff hike, BSNL records growth</a>

Delhi reports over 300 dengue cases in a week; malaria and chikungunya cases on the rise

Data from the <keyword id="19896311" type="General" weightage="20" keywordseo="world-health-organization" source="keywords">World Health Organization</keyword> (WHO) indicates that more than 80% of <keyword id="19897423" type="General" weightage="100" keywordseo="COVID-19" source="keywords">COVID-19</keyword>-related deaths between 2020 and 2021 occurred in people aged 60 and above. Subsequent studies consistently highlighted the increased vulnerability of those over 65 to severe COVID-19 symptoms, and now researchers may have uncovered the reason behind this trend. To comprehend how the corona<keyword id="19994619" type="General" weightage="20" keywordseo="virus" source="keywords">virus</keyword> attacks our bodies, a study investigated the role of our noses, which are the initial point of contact with the virus. Researchers aimed to understand how nasal cells react to the <keyword id="20249557" type="General" weightage="20" keywordseo="SARS-CoV-2" source="keywords">SARS-CoV-2</keyword> virus, hoping to uncover insights for tailored treatment approaches for different age demographics. The study focused on the early impact of SARS-CoV-2 infection on human nasal epithelial cells (NECs). Epithelial cells, abundant throughout our bodies, play crucial roles in bodily functions and protection. Researchers cultured NECs to replicate the nasal cavity's cellular environment and infected them with SARS-CoV-2. Analysing cells from participants across various age brackets, including children (0-11 years), adults (30-50 years), and the <keyword id="19948381" type="General" weightage="20" keywordseo="elderly" source="keywords">elderly</keyword> (over 70 years), the study identified age-specific responses to the virus. Children's NECs quickly increased interferon production upon SARS-CoV-2 exposure, effectively limiting viral replication. In contrast, NECs from older individuals exhibited increased viral replication, accompanied by heightened cell shedding and damage. This disparity may explain why <keyword id="21324937" type="General" weightage="20" keywordseo="older-people" source="keywords">older people</keyword> face a higher risk of severe COVID-19, despite widespread vaccination efforts. Lead author Claire Smith explains, "Our research highlights age-related changes in nasal cells and their impact on our ability to combat SARS-CoV-2 infection. This insight is crucial for developing targeted antiviral treatments, especially for older adults who are at greater risk of severe COVID-19." Understanding age-specific differences in nasal cell response to SARS-CoV-2 could lead to targeted antiviral therapies that boost interferon production in older adults, potentially reducing the severity of COVID-19 and lowering mortality rates in this demographic. Furthermore, the study underscores the importance of considering age as a significant factor in researching and treating infectious diseases. Beyond COVID-19, future studies should explore how <keyword id="19900302" type="General" weightage="20" keywordseo="ageing" source="keywords">ageing</keyword> affects the body's response to other viral infections, informing preventive measures and therapeutic interventions across different age groups. The research findings have been published in Nature Microbiology and can be accessed <a href="http://dx.doi.org/10.1038/s41564-024-01658-1" data-type="tilCustomLink">here</a>.

You Searched For "Covid 19 deaths in Delhi" and got 8 results

'I thought I experienced death': Al Pacino talks about battling Covid-19

BI India Bureau

How did we manage to deal with COVID-19 so quickly, but the common cold still remains a persisting problem?

Ankush Banerjee

Pan-India rollout of U-WIN to track routine immunisations likely by Aug end

PTI

COVID-19 pandemic caused global life expectancy to fall back to 2012 levels, erasing a decade’s worth of progress: WHO

Kunal Kambli

290 cases of COVID-19 variant KP.2, 34 cases of KP.1 detected in India: INSACOG data

PTI

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

ANI

Delhi reports over 300 dengue cases in a week; malaria and chikungunya cases on the rise

BI India Bureau

The ageing of nasal tissues may explain why older people are more affected by COVID-19: research

Ankush Banerjee

Popular Keywords

Buying Guides